2
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
2
Phase 1
1
Status
Completed
3
Recruiting
2
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
1
Conditions
Locally Advanced Non-Small Cell Lung Cancer
1
Leukemia, Myeloid, Acute
1
Hypoxia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
1499
Cisplatin
1435
Paclitaxel
1340
Radiotherapy
1310
Carboplatin
1267
Gemcitabine
1226
Docetaxel
1133
Bevacizumab
1070
Fluorouracil
906
Doxorubicin
805
Dexamethasone
755
Rituximab
744
Capecitabine
735
Oxaliplatin
709
pembrolizumab
700
Etoposide
679
Irinotecan
639
Filgrastim
624
Cytarabine
587
Nivolumab
586
Leucovorin
583
Vincristine
517
Cetuximab
479
Prednisone
478
Bortezomib
474
Trastuzumab
468
Erlotinib Hydrochloride
467
Surveys and Questionnaires
460
Methotrexate
444
Lenalidomide
436
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Atovaquone
×
Clear all
NCT04648033
2026-01-29
ARCADIAN
University of Oxford
Phase 1
Completed
21 enrolled
21 charts
NCT03568994
2026-01-27
ATACC AML
Baylor College of Medicine
Phase EARLY_PHASE1
Completed
26 enrolled
NCT02628080
2019-09-04
ATOM
University of Oxford
Phase EARLY_PHASE1
Completed
46 enrolled